The technology described herein is directed to Natural Killer (NK) cell CAR polypeptides comprising intracellular signaling domains, intracellular costimulatory domains, and/or transmembrane domains from NK-associated polypeptides. In various aspects, described herein are polynucleotides, vectors, or cells expressing said NK CAR polypeptides, and pharmaceutical compositions comprising said NK CAR polypeptides, polynucleotides, vectors, or cells. Also described herein are methods of using said NK CAR polypeptides, for example to treat various diseases and disorders, such as cancer or infectious diseases.

Chlorotoxin derivatives containing amino acid sequence

TABLE-US-00001 X.sub.0X.sub.1CMPCX.sub.S1X.sub.S2X.sub.S3DHX.sub.S4X.sub.S5ARRCX.sub.2X.sub.3CCGGYGX.sub.4CFGYQC LCX.sub.5X.sub.6X.sub.7X.sub.8
wherein (i) the N-terminal X.sub.0X.sub.1 cluster is AM, 0M, or 00; (ii) the solubility X.sub.S1X.sub.S2X.sub.S3X.sub.S4X.sub.S5 cluster is FTTQT, FTTES, SSSQT, SSSES, FSSQT, FSSES, or FSSQS; (iii) the internal X.sub.2X.sub.3X.sub.4 cluster is DKR, RDK, KDR, IKY, HKW, DRK, LKQ, KKK; and (iv) the C-terminal X.sub.5X.sub.6X.sub.7X.sub.8 cluster is N000, R000, NR00, NRG0, NRGY, NRRR, or RRRR;
0 denotes a position where no amino acid is present; the chlorotoxin derivative has a relative human MMP-2 binding that is at least 1.62 times higher than the wild-type chlorotoxin of SEQ ID NO: 1. Conjugates containing the chlorotoxin derivatives and a method for preparing then, theranostic pairs containing the conjugates, kits containing the conjugates or the theranostic pairs, pharmaceutical compositions containing the conjugates, methods of treating cancer, nucleic acid molecules encoding a chimeric antigen receptor which contains the chlorotoxin derivative and vectors containing the nucleic acid.

An engineered immune receptor (e.g., a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR)) that contains one or more short linear motifs that bind to other intracellular signaling proteins are provided, as well as nucleic acids encoding the same, cells that contain the same and methods of use. Examples of such motifs include a PLC?1-binding motifs and TRAF binding motifs, but other motifs may be used. These motifs are thought to recruit other proteins to the engineered immune receptor, thereby altering cellular responses.

Disclosed herein are fibroblast activation protein (FAP)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.

Chimeric antigen receptors targeting CD20 and preparation methods thereof are provided. The antigen binding region of the chimeric antigen receptor may include a heavy chain variable region shown in SEQ ID NOs: 7, 9 or 33 and a light chain variable region shown in SEQ ID NOs: 11, 13 or 35.

Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective use of myeloid cells in combination therapy is described.

Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

The present invention provides compositions and methods for transducing cells (e.g. T cells or immune cells). Also provided herein are methods of treating a disease in a subject in need thereof.

This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.

The present invention provides chimeric antigen receptors (CAR) and methods of use in the treatment of diseases and disorders.